Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $80.23 Average Price Target from Brokerages

by · The Cerbat Gem

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $80.2308.

Several research firms recently issued reports on RARE. Cantor Fitzgerald restated an “overweight” rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Wells Fargo & Company began coverage on Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Finally, TD Cowen cut their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th.

Read Our Latest Stock Report on RARE

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $33.47 on Friday. The firm has a market cap of $3.23 billion, a P/E ratio of -6.05 and a beta of 0.30. The firm’s fifty day moving average is $32.41 and its 200 day moving average is $32.36. Ultragenyx Pharmaceutical has a 52 week low of $25.81 and a 52 week high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The business had revenue of $159.93 million for the quarter, compared to analysts’ expectations of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.40) earnings per share. As a group, analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 7,942 shares of the business’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 10,456 shares of company stock valued at $328,486. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently modified their holdings of RARE. TD Asset Management Inc boosted its position in Ultragenyx Pharmaceutical by 48.1% in the 1st quarter. TD Asset Management Inc now owns 138,484 shares of the biopharmaceutical company’s stock worth $5,015,000 after purchasing an additional 45,000 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Ultragenyx Pharmaceutical by 15.8% during the first quarter. Mackenzie Financial Corp now owns 18,658 shares of the biopharmaceutical company’s stock worth $676,000 after buying an additional 2,543 shares in the last quarter. XTX Topco Ltd boosted its holdings in Ultragenyx Pharmaceutical by 182.5% during the first quarter. XTX Topco Ltd now owns 31,780 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 20,532 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Ultragenyx Pharmaceutical by 231.4% during the first quarter. PNC Financial Services Group Inc. now owns 2,737 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 1,911 shares during the period. Finally, Deutsche Bank AG increased its holdings in Ultragenyx Pharmaceutical by 0.5% in the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after buying an additional 8,385 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Read More